| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.704 | 0.004 | 0.704 | Cyclooxygenase 1 inhibitor | 0.681 0.004 DBMET01313 0.64 0.004 DBMET01315 | ||
| 0.632 | 0.004 | 0.635 | Non-steroidal antiinflammatory agent | 0.635 0.004 DBMET01313 0.58 0.005 DBMET01315 | DBMET01313 | |
| 0.596 | 0.01 | 0.71 | Lipoxygenase inhibitor | 0.71 0.005 DBMET01313 0.645 0.007 DBMET01315 | DBMET01313 | |
| 0.63 | 0.046 | 0.632 | Antiinflammatory | 0.632 0.045 DBMET01313 0.585 0.058 DBMET01315 | DBMET01313 | |
| 0.584 | 0.004 | 0.584 | 5-Lipoxygenase inhibitor | 0.582 0.004 DBMET01313 0.558 0.004 DBMET01315 | ||
| 0.485 | 0.003 | 0.485 | Prostaglandin-E synthase inhibitor | 0.454 0.003 DBMET01313 0.409 0.003 DBMET01315 | ||
| 0.502 | 0.031 | 0.502 | Toll-Like receptor 7 agonist | 0.461 0.04 DBMET01313 0.454 0.042 DBMET01315 | ||
| 0.492 | 0.033 | 0.492 | Toll-Like receptor agonist | 0.451 0.043 DBMET01313 0.445 0.045 DBMET01315 | ||
| 0.423 | 0.006 | 0.423 | Cyclooxygenase inhibitor | 0.406 0.007 DBMET01313 0.392 0.008 DBMET01315 | ||
| 0.353 | 0.038 | 0.37 | Sodium/bile acid cotransporter inhibitor | 0.37 0.029 DBMET01313 0.36 0.034 DBMET01315 | DBMET01313 | |
| 0.381 | 0.093 | 0.381 | Analgesic | 0.366 0.1 DBMET01313 0.324 0.124 DBMET01315 | ||
| 0.304 | 0.048 | 0.304 | Hypolipemic | 0.292 0.051 DBMET01313 0.268 0.06 DBMET01315 | ||
| 0.313 | 0.083 | 0.343 | Cholesterol antagonist | 0.343 0.067 DBMET01313 0.249 0.126 DBMET01315 | DBMET01313 | |
| 0.348 | 0.124 | 0.351 | Cyclophilin D inhibitor | 0.351 0.121 DBMET01313 0.304 0.159 DBMET01315 | DBMET01313 | |
| 0.231 | 0.024 | 0.231 | Cyclooxygenase 2 inhibitor | 0.222 0.025 DBMET01313 0.216 0.027 DBMET01315 | ||
| 0.203 | 0.007 | 0.203 | Prostaglandin antagonist | 0.147 0.01 DBMET01313 0.105 0.016 DBMET01315 | ||
| 0.231 | 0.065 | 0.231 | Anticonvulsant | |||
| 0.261 | 0.107 | 0.274 | Interleukin 2 agonist | 0.274 0.094 DBMET01313 0.248 0.12 DBMET01315 | DBMET01313 | |
| 0.193 | 0.04 | 0.201 | Arachidonic acid antagonist | 0.198 0.035 DBMET01313 0.201 0.032 DBMET01315 | DBMET01315 | |
| 0.199 | 0.049 | 0.199 | Succinate dehydrogenase inhibitor | 0.193 0.054 DBMET01313 0.199 0.049 DBMET01315 | ||
| 0.142 | 0.004 | 0.142 | Prostaglandin D2 antagonist | 0.09 0.005 DBMET01313 0.068 0.005 DBMET01315 | ||
| 0.166 | 0.037 | 0.195 | Cholesterol synthesis inhibitor | 0.195 0.028 DBMET01313 0.136 0.053 DBMET01315 | DBMET01313 | |
| 0.295 | 0.171 | 0.303 | 5 Hydroxytryptamine release inhibitor | 0.303 0.162 DBMET01313 | DBMET01313 | |
| 0.224 | 0.104 | 0.228 | 5 Hydroxytryptamine release stimulant | 0.228 0.101 DBMET01313 0.17 0.153 DBMET01315 | DBMET01313 | |
| 0.174 | 0.058 | 0.174 | Diuretic | 0.145 0.081 DBMET01313 0.159 0.07 DBMET01315 | ||
| 0.117 | 0.004 | 0.117 | MDM2 inhibitor | 0.098 0.008 DBMET01313 0.09 0.012 DBMET01315 | ||
| 0.144 | 0.037 | 0.144 | GABA C receptor agonist | 0.113 0.055 DBMET01313 0.099 0.067 DBMET01315 | ||
| 0.22 | 0.117 | 0.222 | 5 Hydroxytryptamine uptake stimulant | 0.217 0.122 DBMET01313 0.222 0.115 DBMET01315 | DBMET01315 | |
| 0.118 | 0.014 | 0.133 | Aldose reductase inhibitor | 0.133 0.012 DBMET01313 0.102 0.017 DBMET01315 | DBMET01313 | |
| 0.142 | 0.04 | 0.146 | Interleukin 8 antagonist | 0.146 0.037 DBMET01313 0.146 0.037 DBMET01315 | DBMET01315 | |
| 0.189 | 0.088 | 0.229 | Neurotrophic factor enhancer | 0.229 0.052 DBMET01313 0.181 0.097 DBMET01315 | DBMET01313 | |
| 0.1 | 0.006 | 0.1 | Potassium channel subfamily K member 3 blocker | 0.063 0.01 DBMET01313 0.055 0.011 DBMET01315 | ||
| 0.112 | 0.018 | 0.112 | Protein kinase C alpha inhibitor | 0.099 0.023 DBMET01313 0.082 0.032 DBMET01315 | ||
| 0.133 | 0.041 | 0.133 | GABA C receptor antagonist | 0.12 0.053 DBMET01313 0.098 0.082 DBMET01315 | ||
| 0.208 | 0.122 | 0.248 | Tyrosine 3 hydroxylase inhibitor | 0.248 0.069 DBMET01313 0.199 0.137 DBMET01315 | DBMET01313 | |
| 0.085 | 0.006 | 0.085 | Carnitine palmitoyltransferase 1B inhibitor | 0.076 0.009 DBMET01313 0.064 0.014 DBMET01315 | ||
| 0.118 | 0.042 | 0.118 | GABA C receptor rho-1 antagonist | 0.1 0.062 DBMET01313 | ||
| 0.238 | 0.165 | 0.28 | GABA C receptor rho-3 antagonist | 0.28 0.13 DBMET01313 | DBMET01313 | |
| 0.111 | 0.041 | 0.111 | Lanosterol 14 alpha demethylase inhibitor | 0.103 0.051 DBMET01313 | ||
| 0.112 | 0.044 | 0.112 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.086 0.072 DBMET01313 | ||
| 0.091 | 0.026 | 0.091 | Glutamate (mGluR) agonist | 0.064 0.041 DBMET01313 0.062 0.044 DBMET01315 | ||
| 0.084 | 0.019 | 0.084 | Nitric oxide donor | 0.079 0.023 DBMET01313 0.075 0.027 DBMET01315 | ||
| 0.138 | 0.08 | 0.138 | Ca2+-transporting ATPase inhibitor | 0.134 0.099 DBMET01313 | ||
| 0.063 | 0.007 | 0.063 | p53 inhibitor | 0.055 0.011 DBMET01313 0.043 0.018 DBMET01315 | ||
| 0.142 | 0.088 | 0.145 | Thrombolytic | 0.145 0.086 DBMET01313 0.144 0.087 DBMET01315 | DBMET01313 | |
| 0.173 | 0.123 | 0.173 | Platelet antagonist | 0.155 0.139 DBMET01313 | ||
| 0.08 | 0.041 | 0.09 | GABA B receptor agonist | 0.09 0.025 DBMET01313 0.073 0.06 DBMET01315 | DBMET01313 | |
| 0.103 | 0.068 | 0.103 | Ferrochelatase inhibitor | |||
| 0.162 | 0.129 | 0.26 | Aldehyde oxidase inhibitor | 0.26 0.079 DBMET01313 | DBMET01313 | |
| 0.058 | 0.031 | 0.058 | DNA helicase inhibitor | 0.054 0.039 DBMET01313 0.053 0.042 DBMET01315 | ||
| 0.039 | 0.014 | 0.056 | ATP citrate lysase inhibitor | 0.049 0.008 DBMET01313 0.056 0.006 DBMET01315 | DBMET01315 | |
| 0.038 | 0.013 | 0.039 | Protein kinase C beta II inhibitor | 0.039 0.012 DBMET01313 0.034 0.019 DBMET01315 | DBMET01313 | |
| 0.1 | 0.075 | 0.133 | DOPA decarboxylase inhibitor | 0.133 0.032 DBMET01313 0.107 0.063 DBMET01315 | DBMET01313 | |
| 0.036 | 0.015 | 0.047 | Liver X receptor beta antagonist | 0.039 0.013 DBMET01313 0.047 0.009 DBMET01315 | DBMET01315 | |
| 0.261 | 0.24 | 0.311 | Caspase 9 stimulant | 0.311 0.182 DBMET01313 | DBMET01313 | |
| 0.072 | 0.051 | 0.072 | Glycine receptor agonist | 0.066 0.063 DBMET01313 | ||
| 0.162 | 0.143 | 0.173 | Tumour necrosis factor alpha release inhibitor | 0.173 0.132 DBMET01313 | DBMET01313 | |
| 0.198 | 0.18 | 0.198 | Antithrombotic | 0.198 0.18 DBMET01313 | ||
| 0.028 | 0.011 | 0.028 | Retinoid X gamma receptor agonist | 0.022 0.018 DBMET01313 0.023 0.016 DBMET01315 | ||
| 0.09 | 0.074 | 0.099 | Bile acid receptor antagonist | 0.099 0.051 DBMET01313 | DBMET01313 | |
| 0.08 | 0.064 | 0.08 | Transforming growth factor beta 3 antagonist | |||
| 0.107 | 0.093 | 0.125 | Cyclooxygenase 3 inhibitor | 0.125 0.072 DBMET01313 | DBMET01313 | |
| 0.035 | 0.021 | 0.035 | Free fatty acid receptor 1 antagonist | |||
| 0.089 | 0.075 | 0.089 | Electrolyte absorption antagonist | |||
| 0.04 | 0.026 | 0.04 | AMPA 4 receptor antagonist | |||
| 0.025 | 0.011 | 0.025 | Retinoid X beta receptor agonist | 0.019 0.016 DBMET01313 0.021 0.014 DBMET01315 | ||
| 0.06 | 0.047 | 0.06 | NMDA receptor agonist | |||
| 0.035 | 0.022 | 0.035 | HMG CoA reductase inhibitor | 0.033 0.026 DBMET01313 0.032 0.029 DBMET01315 | ||
| 0.053 | 0.04 | 0.062 | Protein kinase C eta inhibitor | 0.062 0.033 DBMET01313 | DBMET01313 | |
| 0.058 | 0.047 | 0.058 | NMDA receptor glycine site agonist | |||
| 0.094 | 0.084 | 0.161 | Cystathionine beta-synthase inhibitor | 0.15 0.041 DBMET01313 0.161 0.036 DBMET01315 | DBMET01315 | |
| 0.062 | 0.055 | 0.077 | Potassium channel large-conductance Ca-activated activator | 0.077 0.037 DBMET01313 | DBMET01313 | |
| 0.206 | 0.202 | 0.206 | Antiobesity | |||
| 0.039 | 0.035 | 0.039 | Kainate receptor agonist | |||
| 0.025 | 0.022 | 0.025 | 11-Beta-hydroxysteroid dehydrogenase 2 inhibitor | |||
| 0.031 | 0.029 | 0.031 | Retinoid X alpha receptor agonist | |||
| 0.043 | 0.042 | 0.043 | Thromboxane A2 antagonist | |||
| 0.082 | 0.081 | 0.082 | ABCA1 expression enhancer | |||
| 0.124 | 0.124 | 0.141 | Interferon gamma antagonist | 0.141 0.09 DBMET01313 0.127 0.117 DBMET01315 | DBMET01313 | |
| 0.035 | 0.039 | 0.038 | Liver X receptor alpha agonist | 0.038 0.033 DBMET01313 | DBMET01313 | |
| 0.03 | 0.035 | 0.042 | NMDA receptor subunit 3A antagonist | 0.042 0.024 DBMET01313 | DBMET01313 | |
| 0.03 | 0.036 | 0.032 | Protein kinase C beta I inhibitor | 0.032 0.029 DBMET01313 | DBMET01313 | |
| 0.035 | 0.044 | 0.046 | NMDA receptor subunit 3B antagonist | 0.046 0.029 DBMET01313 0.039 0.036 DBMET01315 | DBMET01313 | |
| 0.156 | 0.169 | 0.195 | Hypoglycemic | 0.195 0.117 DBMET01313 | DBMET01313 | |
| 0.072 | 0.085 | 0.098 | Potassium channel (Ca-activated) activator | 0.098 0.057 DBMET01313 | DBMET01313 | |
| 0.194 | 0.209 | 0.226 | Histamine release inhibitor | 0.226 0.175 DBMET01313 | DBMET01313 | |
| 0.068 | 0.083 | 0.091 | NMDA receptor antagonist | 0.091 0.053 DBMET01313 | DBMET01313 | |
| 0.051 | 0.071 | 0.06 | Leukotriene synthesis inhibitor | 0.06 0.056 DBMET01313 | DBMET01313 | |
| 0.13 | 0.155 | 0.143 | Phospholipase C inhibitor | 0.143 0.122 DBMET01313 | DBMET01313 | |
| 0.125 | 0.151 | 0.141 | Lipocortins synthesis antagonist | 0.141 0.119 DBMET01315 | DBMET01315 | |
| 0.156 | 0.192 | 0.17 | DNA synthesis inhibitor | 0.17 0.168 DBMET01315 | DBMET01315 | |
| 0.11 | 0.15 | 0.125 | Adenylate cyclase stimulant | 0.125 0.113 DBMET01313 | DBMET01313 | |
| 0.045 | 0.091 | 0.066 | Histidine decarboxylase inhibitor | 0.066 0.055 DBMET01313 | DBMET01313 | |
| 0.109 | 0.174 | 0.135 | Hepatoprotectant | 0.135 0.127 DBMET01313 | DBMET01313 | |
| 0.061 | 0.129 | 0.1 | Creatine kinase inhibitor | 0.1 0.059 DBMET01313 | DBMET01313 | |
| 0.196 | 0.279 | 0.265 | Apoptosis agonist | 0.265 0.199 DBMET01313 0.247 0.218 DBMET01315 | DBMET01313 | |
| 0.057 | 0.17 | 0.117 | Estrogen receptor beta antagonist | 0.115 0.038 DBMET01313 0.117 0.035 DBMET01315 | DBMET01315 | |
| 0.085 | 0.201 | 0.119 | Farnesoid X receptor antagonist | 0.119 0.106 DBMET01313 | DBMET01313 | |
| 0.05 | 0.169 | 0.071 | Estrogen receptor alpha antagonist | 0.071 0.065 DBMET01315 | DBMET01315 | |
| 0.067 | 0.198 | 0.126 | Estrogen antagonist | 0.126 0.045 DBMET01313 0.126 0.045 DBMET01315 | DBMET01315 | |
| 0.123 | 0.262 | 0.197 | Transcription factor NF kappa B inhibitor | 0.197 0.172 DBMET01313 | DBMET01313 | |
| 0.162 | 0.355 | 0.231 | Calcium channel L-type activator | 0.231 0.228 DBMET01313 | DBMET01313 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |